event tracking

Clinical Trials

30 results.

April 3, 2024 Phase 2 clinical trial of Type 2 diabetes drug for treatment of Parkinson’s shows positive and promising results

LONDON (April 3, 2024) — Results from a one-year, phase 2 clinical trial of the Type 2 diabetes drug lixisenatide suggest that the treatment may…

February 23, 2024 Cure Parkinson's and Van Andel Institute fund Phase 2 clinical trial of dapansutrile for Parkinson’s

LONDON (Feb. 23, 2024) — Cure Parkinson’s and Van Andel Institute are delighted to announce funding for a Phase 2 clinical trial…

February 15, 2024 How a ‘blockbuster’ treatment for diabetes and obesity might slow or stop Parkinson’s

A “blockbuster” weight loss medication hailed as the “2023 Breakthrough of the Year” by Science also may have game-changing implications for Parkinson’s…

August 28, 2023 Preliminary phase 2 trial results of lixisenatide presented

Copenhagen, Denmark (August 28, 2023) — A one-year, phase 2 clinical trial of Type 2 diabetes drug lixisenatide has reported positive early results, which indicate…

March 13, 2023 Van Andel Institute, Cure Parkinson’s renew $4.5 million co-funding agreement to support collaborative Parkinson’s clinical trials program

Grand Rapids, Mich. (March 13, 2023) — Cure Parkinson’s and Van Andel Institute (VAI) are delighted to announce that their co-funding agreement, which supports…

January 10, 2023 Cough medicine offers hope of new treatment to slow the progression of Parkinson’s disease

London, United Kingdom (Jan. 10, 2023) — Following promising results reported at Phase 2 in 2020, a large-scale Phase 3 clinical trial of ambroxol,…

November 1, 2022 Combining two cancer medications may increase survival in relapsed myelodysplastic syndrome, lays groundwork for future cancer therapies

GRAND RAPIDS, Mich. (Nov. 1, 2022) — A pair of cancer medications that act as a one-two punch against malignant cells demonstrated increased survival in…